Truist Financial Lowers Boston Scientific (NYSE:BSX) Price Target to $57.00

Boston Scientific (NYSE:BSX) had its price objective dropped by analysts at Truist Financial from $62.00 to $57.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price objective would indicate a potential upside of 21.94% from the stock’s previous close.

BSX has been the subject of a number of other reports. Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Barclays reduced their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. UBS Group restated a “buy” rating and set a $74.00 target price (down from $95.00) on shares of Boston Scientific in a report on Tuesday. Jefferies Financial Group dropped their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Trading Up 1.6%

NYSE BSX opened at $46.75 on Thursday. The stock has a market cap of $69.48 billion, a PE ratio of 18.93, a PEG ratio of 0.94 and a beta of 0.58. Boston Scientific has a 12 month low of $42.20 and a 12 month high of $109.50. The company’s 50-day moving average price is $46.13 and its 200-day moving average price is $62.26. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.36%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts forecast that Boston Scientific will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 9,800 shares of company stock worth $554,012 over the last quarter. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in the stock. Cary Street Partners Financial LLC boosted its position in shares of Boston Scientific by 16.7% during the 2nd quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock valued at $1,071,000 after acquiring an additional 3,597 shares during the last quarter. Farther Finance Advisors LLC grew its position in Boston Scientific by 28.9% in the second quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock worth $1,227,000 after acquiring an additional 6,427 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Boston Scientific by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock worth $2,106,000 after purchasing an additional 1,119 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in Boston Scientific by 32.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock valued at $641,000 after buying an additional 3,690 shares during the period. Finally, Riversedge Advisors LLC acquired a new position in Boston Scientific in the second quarter valued at about $320,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.